NCT03060577: A reported trial by Novartis Pharmaceuticals
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT03060577 |
|---|---|
| Title | An Open Label, Active Comparator Extension Trial to Assess the Effect of Long Term Dosing of Inclisiran and Evolocumab Given as Subcutaneous Injections in Participants With High Cardiovascular Risk and Elevated LDL-C (ORION-3) |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | April 27, 2017 |
| Completion date | Dec. 17, 2021 |
| Required reporting date | Dec. 17, 2022, midnight |
| Actual reporting date | Nov. 28, 2022 |
| Date last checked at ClinicalTrials.gov | Feb. 9, 2024 |
| Days late | None |